Comparison of Oral Semaglutide w/ Placebo- Treatment for Latino Adults w/T2 Diabetes Receiving Enhanced Lifestyle Care

NCT04938388 on ClinicalTrials.gov · last registry update 2023-05-25

Stopped early, having planned 12 participants. The sponsor logged completion for 16 February 2023. Primary outcome, as filed: HbA1c < 7.0%. semaglutide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status: TERMINATED
Phase: P4
Drug: semaglutide
Ozempic, Rybelsus, Wegovy
Sponsor: Sansum Diabetes Research Institute
Sponsor type: Other
Enrollment: 12
Started: 2022-01-29
Primary completion: 2023-02-16 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

HbA1c < 7.0%

Conditions studied

Diabetes Mellitus, Type 2 · Glucose Metabolism Disorders (Including Diabetes Mellitus)

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.